

March 5, 2015  
Sysmex Corporation

## Announcement of Organizational and Personnel Changes

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today its decision to implement organizational and personnel changes, effective April 1, 2015, as detailed below.

These organizational changes are intended to enhance the level of management and accelerate strategic implementation by augmenting functionality across businesses to achieve greater Group synergies. In addition, these changes put in place a structure to further promote business in non-hematology fields<sup>1</sup>.

---

### 1. Organizational Changes

#### (1) Enhancing the Level of Management

##### a) Strengthening the Business Planning Function to Enhance Group Management

- We will establish the Corporate Business Planning Division as a dedicated organization. In addition to creating management strategy and business plans, the division will be tasked with providing support to enable agile decision-making by top management in light of increasingly sophisticated businesses and technologies.

##### b) Augmenting the Corporate Communications Function to Meet the Needs of Diverse Stakeholders

- We will newly establish the Corporate Communication Division. In addition to conducting brand promotion activities to augment corporate value and spread awareness of the Company's future prospects, the division will conduct CSR and environmental activities with the aim of fostering bilateral communications to enhance Sysmex's prestige and bolstering overall management quality.

#### (2) Accelerating Strategic Implementation

##### a) Augmenting Functionality across Businesses to Achieve Greater Group Synergies

- We will newly establish the Solution Development Division to consolidate functions related to product development and manufacturing across fields; promote product development employing network solutions, laboratory automation and FCM<sup>2</sup> technology; and support efforts to build value in each business unit.


- In line with the Group's increasing scale, we will establish the Manufacturing Management Division to consolidate functions related to production planning and production technology in the aim of increasing instrument and reagent production efficiency and strengthening our ability to meet our responsibility for supplying these products.
  - To enhance the regulatory application process, we will relocate the Technology Development Division's Clinical Development Department to the Regulatory Affairs & Quality Assurance Division's Regulatory Affairs Department and combine these departments, thereby creating an integrated process spanning clinical trials and clinical studies to regulatory applications.
  - To create clinical value across fields and enhance validation, we will redefine the roles of the Scientific Affairs Division's Scientific Research Department and Scientific Marketing Department and restructuring these departments.
- b) Buttressing the Business Promotion Function to Match the Business Environment
- To expand our business in the research and industry domains, including entry into the research-oriented flow cytometry market, we will combine the New Business Development Division and the FCM Business Planning Department, newly establishing the Research & Industry Business Division.
  - We will newly establish the Biological Material Center within the ICH Business Unit to formulate Group production strategies on biological materials for diagnostic reagents, as well as to oversee their development, production and the development of production technologies.
  - To augment our product development function related to cervical cancer screening, we will conduct an expansive reorganization of the Product Development Department, establishing within the UB Product Engineering Division the Product Development 1 Department, which will take charge of urinalysis, and the Product Development 2 Department, which will handle cervical cancer.
  - We will expansively reorganize our Production Department in accordance with increased production volumes and a growing number of products. In this reorganization, within the Instrument Production Division we will establish the Production 1 Department, to be in charge of i-Square, and the Production 2 Department, taking charge of the Kakogawa Factory.

1 Non-hematology fields: *in-vitro* diagnostics fields excluding hematology but including immunochemistry, clinical chemistry, hemostasis, urinalysis and


others.

2 Flow cytometry (FCM): Method involving the flow dispersion of minute particles and the use of laser light to optically analyze the minute flows. Used primarily to observe individual cells.

### New Organizational Structure



### Previous Organizational Structure



## 2. Personnel Changes and Appointments

## (1) Appointments of Senior Executive Officers (Promotions)

Name	New Position	Current Position
Kaoru Asano	Member of the Managing Board and Senior Executive Officer Managing Director	Member of the Managing Board and Senior Executive Officer
Kenji Tachibana	Member of the Managing Board and Senior Executive Officer Managing Director	Member of the Managing Board and Senior Executive Officer
Junzo Yamamoto	Senior Executive Officer	Executive Officer

## (2) Appointments of Executive Officers (Newly Appointed)

Name	New Position
Juergen Schulze	Executive Officer
Mamoru Kubota	Executive Officer

**(3) Changes in Operating and Functional Changes of Executive Officers**

Name	New Position	Current Position
Yukio Nakajima	Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Corporate Business Planning Div. Corporate Communication Div. Corporate Business Administration Div. Human Resources & General Affairs Div. Corporate Executive Office Sysmex Business Support Co., Ltd.	Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Corporate Business Planning Div. Corporate Business Administration Div. Human Resources & General Affairs Div. Corporate Executive Office Sysmex Business Support Co., Ltd.
Koji Tamura	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; LS Business Unit Life Science Product Engineering Div. Sysmex Inostics GmbH	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; LS Business Unit Life Science Product Engineering Div. New Business Development Div. Sysmex Inostics GmbH
Mitsuru Watanabe	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; HU Business Unit Hematology Product Engineering Div. UB Product Engineering Div. Business Management Dept.	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; HU Business Unit Hematology Product Engineering Div. UB Product Engineering Div. Business Management Dept. FCM Business Planning Dept. Sysmex Partec GmbH

Name	New Position	Current Position
Kaoru Asano	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; R&D Strategic Planning Div. Central Research Laboratories Technology Development Div. Mediaroid Corporation Sysmex Engineering Co.,Ltd. RIKEN GENESIS CO., LTD. Vice President of Mediaroid Corporation Director of RIKEN GENESIS CO., LTD.	Member of the Managing Board and Senior Executive Officer In charge of; R&D Strategic Planning Div. Central Research Laboratories Technology Development Div. Mediaroid Corporation Sysmex Engineering Co.,Ltd. RIKEN GENESIS CO., LTD. Executive Vice President of Central Research Laboratories Vice President of Mediaroid Corporation Director of RIKEN GENESIS CO., LTD.
Kenji Tachibana	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; Business Strategy Development Div. Executive Vice President of Business Strategy Development Div.	Member of the Managing Board and Senior Executive Officer In charge of; Business Strategy Development Div. Executive Vice President of Business Strategy Development Div.
Michiaki Ishida	Senior Executive Officer In charge of; ICH Business Unit Immunology & Chemistry Product Engineering Div. Hemostasis Product Engineering Div. Business Management Dept. Biological Material Center Sysmex International Reagents Co., Ltd. HYPHEN BioMed, SAS Sysmex Wuxi Co., Ltd.	Senior Executive Officer In charge of; ICH Business Unit Immunology & Chemistry Product Engineering Div. Hemostasis Product Engineering Div. Business Management Dept. Sysmex International Reagents Co., Ltd. HYPHEN BioMed, SAS Sysmex Wuxi Co., Ltd.

Name	New Position	Current Position
Takashi Goda	Senior Executive Officer In charge of; Research & Industry Business Div. Solution Development Div. Sysmex Partec GmbH Executive Vice President of Solution Development Div.	Senior Executive Officer In charge of; Business Management (Japan) Div. Sales & Marketing East / Japan Div. Sales & Marketing West / Japan Div. Sysmex TMC Co., Ltd Sysmex CNA Co., Ltd. Sysmex bioMérieux Co., Ltd.
Junzo Yamamoto	Senior Executive Officer In charge of; Manufacturing Management Div. Instrument Production Div. SCM Div. Sysmex RA Co., Ltd. Sysmex Medica Co., Ltd. Executive Vice President of Instrument Production Div.	Executive Officer In charge of; Instrument Production Div. SCM Div. Sysmex RA Co., Ltd. Sysmex Medica Co., Ltd. Executive Vice President of Instrument Production Div.
Iwane Matsui	Executive Officer In charge of; Business Management (Japan) Div. Sales & Marketing East / Japan Div. Sales & Marketing West / Japan Div. Sysmex TMC Co., Ltd Sysmex CNA Co., Ltd. Sysmex bioMérieux Co., Ltd.	Executive Officer Executive Vice President of International Business Management Div. Vice President of EMEA & Americas Business Management Dept.
Keiji Fujimoto	Executive Officer In charge of; Regulatory Affairs & Quality Assurance Div. Scientific Affairs Div. Customer Support Div.	Executive Officer In charge of; Regulatory Affairs & Quality Assurance Div. Scientific Affairs Div. Customer Support Div. Executive Vice President of Regulatory Affairs & Quality Assurance Div.
Juergen Schulze	Executive Officer President and CEO, Sysmex Europe GmbH	President and CEO, Sysmex Europe GmbH



Name	New Position	Current Position
Mamoru Kubota	Executive Officer Executive Vice President of LS Business Unit Life Science Product Engineering Div.	Executive Vice President of LS Business Unit Life Science Product Engineering Div. Vice President of Business Development Dept.